Privia Health Reports Q4 Earnings Beat Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy PRVA?
Source: seekingalpha
- Earnings Beat: Privia Health reported a Q4 non-GAAP EPS of $0.25, exceeding expectations by $0.06, indicating a robust improvement in profitability that may attract increased investor interest.
- Significant Revenue Growth: The company achieved Q4 revenue of $541 million, representing a 17.4% year-over-year increase and surpassing analyst expectations by $22.63 million, reflecting strong competitive positioning and customer demand recovery.
- Value-Based Care Model: With the introduction of CMS's new accountable care model, Privia Health is expected to benefit significantly, further expanding its value-based care services and enhancing its market position.
- Support from Historical Data: Historical financial data for Privia Health indicates stability in earnings and revenue growth, laying a solid foundation for future business development and bolstering investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRVA
Wall Street analysts forecast PRVA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 23.300
Low
23.00
Averages
30.40
High
34.00
Current: 23.300
Low
23.00
Averages
30.40
High
34.00
About PRVA
Privia Health Group, Inc. is a technology-driven, national physician-enablement company. The Company collaborates with medical groups, health plans and health systems. It enhances physician practices, improves patient experiences and doctors for delivering care in both in-person and virtual care settings. Its Privia Platform is powered by the Privia Technology Solution, an end-to-end, cloud-based technology solution that integrates both Privia-developed and third-party applications into an interface and workflow that manages all aspects of its Privia Providers provision of healthcare services. Privia Platform optimizes provider workflow across the full continuum of reimbursement arrangements. The Company provides management services to each Medical Group though a local management services organization, which provides Medical Groups with access to value-based care (VBC) opportunities either directly or through Privia-owned accountable care organizations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
BlackBarn Capital Increases Warby Parker Stake to 3 Million Shares
- Share Increase: According to a recent SEC filing dated February 17, 2026, BlackBarn Capital Partners LP acquired an additional 2 million shares of Warby Parker, raising its total stake to 3 million shares, with an estimated transaction value of $43.52 million, reflecting confidence in the company's growth potential.
- Asset Management Proportion: Warby Parker now accounts for 4.3% of BlackBarn Capital's reportable assets under management, indicating its significance in the firm's 13F report and investor recognition of its potential value.
- Market Performance: As of February 13, 2026, Warby Parker shares were priced at $22.46, down 15% over the past year and underperforming the S&P 500 by 26.8 percentage points, highlighting market concerns regarding its future growth.
- Business Model Analysis: Warby Parker challenges traditional eyewear retail economics through a direct-to-consumer model, and while facing high costs and competitive pressures, its expanding exam capacity may ultimately be key to its future profitability.
See More
EHR-Enabled Colorectal Cancer Screening Achieves Significant Impact
- Screening Rate Increase: The colorectal cancer screening program led by Privia Health achieved an 84% screening rate in 2024, surpassing national benchmarks and the National Colorectal Cancer Roundtable's 80% goal, demonstrating the effectiveness of data-driven patient engagement models.
- Patient Engagement Scale: The program successfully engaged over 42,000 patients through automated outreach, with plans to expand nationally to over 100,000 patients, significantly enhancing the reach and efficiency of screenings.
- Diagnostic Follow-Up Rate: Within a 48-hour window, approximately 23,000 screening orders were processed, yielding a 10% positivity rate that identified over 550 patients requiring further diagnostic follow-up, indicating the program's potential in early cancer detection.
- Support for Value-Based Care: The initiative not only improved screening outcomes but also strengthened patient identification and documentation quality, supporting electronic clinical quality measure (eCQM) reporting and positioning health systems to meet future digital quality measurement requirements.
See More
Privia Health Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Performance Growth: Privia Health's practice collections increased by 16.9% to $3.47 billion in 2025, while adjusted EBITDA grew by 38.8% to $125.5 million, demonstrating the company's strong execution and growth potential in the market.
- Provider Expansion: The addition of 591 new providers resulted in a year-over-year growth rate of 12.3%, bringing the total implemented providers to 5,380, with expectations to reach 5,950 by the end of 2026, further solidifying market position.
- Successful Acquisition Integration: The completion of the Evolent Health ACO business acquisition added over 120,000 value-based attributed lives, marking the company's expansion into Arizona and strengthening the foundation for future growth.
- Optimistic Cash Flow Outlook: The company projects approximately 20% growth in adjusted EBITDA for 2026, with an 80% conversion rate to free cash flow, maintaining around $600 million in cash reserves to support future business development.
See More
Privia Health (PRVA) Q4 2025 Earnings Transcript
See More
Privia Health Reports Q4 Earnings Beat Expectations
- Earnings Beat: Privia Health reported a Q4 non-GAAP EPS of $0.25, exceeding expectations by $0.06, indicating a robust improvement in profitability that may attract increased investor interest.
- Significant Revenue Growth: The company achieved Q4 revenue of $541 million, representing a 17.4% year-over-year increase and surpassing analyst expectations by $22.63 million, reflecting strong competitive positioning and customer demand recovery.
- Value-Based Care Model: With the introduction of CMS's new accountable care model, Privia Health is expected to benefit significantly, further expanding its value-based care services and enhancing its market position.
- Support from Historical Data: Historical financial data for Privia Health indicates stability in earnings and revenue growth, laying a solid foundation for future business development and bolstering investor confidence.
See More
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
- Stake Increase: BlackBarn Capital increased its stake in Warby Parker by 2 million shares during Q4 2025, with an estimated transaction value of $43.52 million, indicating confidence in the company despite a 15% decline in its stock price over the past year.
- Value Appreciation: The value of Warby Parker's position rose by $37.79 million at quarter-end, reflecting the impact of trading activity and stock price fluctuations, suggesting that BlackBarn Capital's investment strategy is proving effective.
- Asset Allocation Shift: Following the increase, Warby Parker now accounts for 4.3% of BlackBarn Capital's 13F reportable assets, indicating its significance in the investment portfolio, even though it does not rank among the top five holdings.
- Market Performance Insight: As of February 13, 2026, Warby Parker shares were priced at $22.46, underperforming the S&P 500 by 26.8 percentage points, prompting investors to monitor the company's ability to achieve sustainable growth in the optical retail market.
See More
BlackBarn Capital Increases Warby Parker Stake to 3 Million Shares
- Share Increase: According to a recent SEC filing dated February 17, 2026, BlackBarn Capital Partners LP acquired an additional 2 million shares of Warby Parker, raising its total stake to 3 million shares, with an estimated transaction value of $43.52 million, reflecting confidence in the company's growth potential.
- Asset Management Proportion: Warby Parker now accounts for 4.3% of BlackBarn Capital's reportable assets under management, indicating its significance in the firm's 13F report and investor recognition of its potential value.
- Market Performance: As of February 13, 2026, Warby Parker shares were priced at $22.46, down 15% over the past year and underperforming the S&P 500 by 26.8 percentage points, highlighting market concerns regarding its future growth.
- Business Model Analysis: Warby Parker challenges traditional eyewear retail economics through a direct-to-consumer model, and while facing high costs and competitive pressures, its expanding exam capacity may ultimately be key to its future profitability.
See More
EHR-Enabled Colorectal Cancer Screening Achieves Significant Impact
- Screening Rate Increase: The colorectal cancer screening program led by Privia Health achieved an 84% screening rate in 2024, surpassing national benchmarks and the National Colorectal Cancer Roundtable's 80% goal, demonstrating the effectiveness of data-driven patient engagement models.
- Patient Engagement Scale: The program successfully engaged over 42,000 patients through automated outreach, with plans to expand nationally to over 100,000 patients, significantly enhancing the reach and efficiency of screenings.
- Diagnostic Follow-Up Rate: Within a 48-hour window, approximately 23,000 screening orders were processed, yielding a 10% positivity rate that identified over 550 patients requiring further diagnostic follow-up, indicating the program's potential in early cancer detection.
- Support for Value-Based Care: The initiative not only improved screening outcomes but also strengthened patient identification and documentation quality, supporting electronic clinical quality measure (eCQM) reporting and positioning health systems to meet future digital quality measurement requirements.
See More
Privia Health Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Performance Growth: Privia Health's practice collections increased by 16.9% to $3.47 billion in 2025, while adjusted EBITDA grew by 38.8% to $125.5 million, demonstrating the company's strong execution and growth potential in the market.
- Provider Expansion: The addition of 591 new providers resulted in a year-over-year growth rate of 12.3%, bringing the total implemented providers to 5,380, with expectations to reach 5,950 by the end of 2026, further solidifying market position.
- Successful Acquisition Integration: The completion of the Evolent Health ACO business acquisition added over 120,000 value-based attributed lives, marking the company's expansion into Arizona and strengthening the foundation for future growth.
- Optimistic Cash Flow Outlook: The company projects approximately 20% growth in adjusted EBITDA for 2026, with an 80% conversion rate to free cash flow, maintaining around $600 million in cash reserves to support future business development.
See More
Privia Health (PRVA) Q4 2025 Earnings Transcript
See More
Privia Health Reports Q4 Earnings Beat Expectations
- Earnings Beat: Privia Health reported a Q4 non-GAAP EPS of $0.25, exceeding expectations by $0.06, indicating a robust improvement in profitability that may attract increased investor interest.
- Significant Revenue Growth: The company achieved Q4 revenue of $541 million, representing a 17.4% year-over-year increase and surpassing analyst expectations by $22.63 million, reflecting strong competitive positioning and customer demand recovery.
- Value-Based Care Model: With the introduction of CMS's new accountable care model, Privia Health is expected to benefit significantly, further expanding its value-based care services and enhancing its market position.
- Support from Historical Data: Historical financial data for Privia Health indicates stability in earnings and revenue growth, laying a solid foundation for future business development and bolstering investor confidence.
See More
